Loss of libido adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,834 adverse event reports that record the MedDRA preferred term Loss of libido. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 515 reports in the 12 months to June 2026 and 693 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 972 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 515 (under 0.1%) record this term. Reports for patients aged 18 to 44 were 45.9% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 146 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Loss of libido name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	55
Acetaminophen Oxycodone Hydrochloride		21
Amisulpride	Dopamine-2 receptor antagonist	17
Amlodipine	Calcium channel blocker	30
Androgel		91
Aripiprazole	Atypical antipsychotic	75
Atenolol	beta-Adrenergic blocker	27
Atorvastatin		81
Auvelity	Aminoketone	11
Avodart		43
Axiron		15
Bicalutamide	Androgen receptor inhibitor	12
Brintellix		14
Buprenorphine	Partial opioid agonist	17
Bupropion	Aminoketone	26
Bupropion hydrochloride	Aminoketone	32
Butrans	Partial opioid agonist	12
Celexa	Serotonin reuptake inhibitor	11
Chantix	Partial cholinergic nicotinic agonist	31
Cialis	Phosphodiesterase 5 inhibitor	11
Cipralex		33
Ciprofloxacin	Fluoroquinolone antibacterial	10
Cisplatin	Platinum-based drug	14
Citalopram	Serotonin reuptake inhibitor	205
Citalopram hydrobromide	Serotonin reuptake inhibitor	49
Citalopram Hydrobromide - Bp		14
Clonidine	Central alpha-2 adrenergic agonist	13
Clozapine	Atypical antipsychotic	44
Clozaril	Atypical antipsychotic	24
Crestor	HMG-CoA reductase inhibitor	12
Cymbalta		112
Depo-Provera	Progestin	60
Desoximetasone	Corticosteroid	15
Desvenlafaxine succinate	Serotonin and norepinephrine reuptake inhibitor	20
Dilaudid	Opioid agonist	33
Docetaxel	Microtubule inhibitor	46
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	29
Dutasteride	5-alpha reductase inhibitor	18
Effexor	Serotonin and norepinephrine reuptake inhibitor	58
Eligard	Gonadotropin releasing hormone receptor agonist	98
Enzalutamide	Androgen receptor inhibitor	10
Escitalopram	Serotonin reuptake inhibitor	213
Escitalopram oxalate	Serotonin reuptake inhibitor	25
Estradiol	Estrogen	14
Euthyrox		36
Ezetimibe	Dietary cholesterol absorption inhibitor	17
Finasteride	5-alpha reductase inhibitor	1,051
Flomax		10
Fluoxetine	Serotonin reuptake inhibitor	151
Fluoxetine hydrochloride	Serotonin reuptake inhibitor	11
Fluvoxamine		40
Gabapentin	Anti-epileptic agent	18
Humira		15
Hydrocodone bitartrate and acetaminophen	Opioid agonist	51
Hydromorphone hydrochloride	Opioid agonist	10
Hydromorphone Tablets		10
Ibuprofen	Nonsteroidal anti-inflammatory drug	11
Implanon		22
Infliximab	Tumor necrosis factor blocker	18
Invega	Atypical antipsychotic	24
Invega Sustenna	Atypical antipsychotic	58
Isotretinoin	Retinoid	63
Jaydess		25
Keppra		10
Klonopin	Benzodiazepine	11
Kyleena	Progestin	25
Lacosamide		18
Lamictal	Anti-epileptic agent	12
Lamotrigine	Anti-epileptic agent	22
Latuda	Atypical antipsychotic	16
Levetiracetam		39
Levothyroxine		11
Lexapro	Serotonin reuptake inhibitor	53
Lisinopril	Angiotensin converting enzyme inhibitor	10
Lorazepam	Benzodiazepine	15
Lupron		19
Lupron Depot		51
Luvox		29
Lyrica		26
Methotrexate	Folate analog metabolic inhibitor	10
Minoxidil	Arteriolar vasodilator	49
Mirena	Progestin	1,376
Mirtazapine		73
Morphine sulfate	Opioid agonist	41
MS Contin	Opioid agonist	25
Nexplanon	Progestin	62
Novothyrox		185
Nuvaring	Estrogen	35
Olanzapine	Atypical antipsychotic	24
Orgovyx	Gonadotropin releasing hormone receptor antagonist	118
Oxycodone	Opioid agonist	12
Oxycodone and acetaminophen	Opioid agonist	35
Oxycodone hydrochloride	Opioid agonist	97
OxyContin	Opioid agonist	89
Paliperidone	Atypical antipsychotic	33
Paliperidone palmitate	Atypical antipsychotic	22
ParaGard T 380A	Copper-containing intrauterine device	19
Paroxetine	Serotonin reuptake inhibitor	125
Paroxetine hydrochloride	Serotonin reuptake inhibitor	88
Paxil	Serotonin reuptake inhibitor	109
Percocet	Opioid agonist	21
Pluvicto		23
Pregabalin		27
Propecia	5-alpha reductase inhibitor	718
Proscar	5-alpha reductase inhibitor	122
Prozac	Serotonin reuptake inhibitor	55
Quetiapine	Atypical antipsychotic	76
Quetiapine fumarate	Atypical antipsychotic	32
Radiation Therapy		13
Ramipril	Angiotensin converting enzyme inhibitor	12
Revlimid	Thalidomide analog	24
Rexulti	Atypical antipsychotic	13
Risperdal	Atypical antipsychotic	48
Risperdal Consta		11
Risperidone	Atypical antipsychotic	63
Rogaine		10
Rosuvastatin	HMG-CoA reductase inhibitor	23
Seroquel	Atypical antipsychotic	18
Seroxat		29
Sertraline	Serotonin reuptake inhibitor	357
Sertraline hcl	Serotonin reuptake inhibitor	21
Sertraline hydrochloride	Serotonin reuptake inhibitor	37
Spironolactone	Aldosterone antagonist	13
Strattera	Norepinephrine reuptake inhibitor	15
Suboxone	Opioid antagonist	19
Synthroid	l-Thyroxine	11
Tamsulosin		16
Temazepam	Benzodiazepine	19
Testosterone	Androgen	22
Topiramate		31
Tramadol		25
Tramadol hydrochloride	Opioid agonist	11
Trazodone		24
Trazodone hydrochloride	Serotonin reuptake inhibitor	10
Trintellix		16
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	107
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	53
Viagra	Phosphodiesterase 5 inhibitor	15
Vivitrol		14
Xanax	Benzodiazepine	12
Xtandi	Androgen receptor inhibitor	23
Yasmin		22
Yaz		11
Zoloft	Serotonin reuptake inhibitor	73
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	11
Zyprexa	Atypical antipsychotic	14

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 10 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Loss of libido name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	1,911
Aldosterone antagonist	16
alpha-Adrenergic blocker	11
Aminoketone	78
Androgen	36
Androgen receptor inhibitor	49
Angiotensin 2 receptor blocker	19
Angiotensin converting enzyme inhibitor	24
Anti-epileptic agent	83
Aromatase inhibitor	20
Arteriolar vasodilator	49
Atypical antipsychotic	651
Benzodiazepine	78
beta-Adrenergic blocker	29
Calcium channel blocker	30
Central alpha-2 adrenergic agonist	15
Central nervous system stimulant	19
Copper-containing intrauterine device	19
Corticosteroid	28
Dietary cholesterol absorption inhibitor	19
Dopamine-2 receptor antagonist	20
Estrogen	72
Fluoroquinolone antibacterial	12
Folate analog metabolic inhibitor	18
gamma-Aminobutyric acid A receptor positive modulator	15
GLP-1 receptor agonist	19
Gonadotropin releasing hormone receptor agonist	119
Gonadotropin releasing hormone receptor antagonist	125
HMG-CoA reductase inhibitor	62
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	17
Kinase inhibitor	12
l-Thyroxine	13
Microtubule inhibitor	46
Mood stabilizer	24
Nonsteroidal anti-inflammatory drug	20
Norepinephrine reuptake inhibitor	17
Opioid agonist	474
Opioid antagonist	19
Partial cholinergic nicotinic agonist	34
Partial opioid agonist	33
Peroxisome proliferator receptor alpha agonist	14
Phosphodiesterase 5 inhibitor	36
Platinum-based drug	23
Progestin	1,535
Proton pump inhibitor	21
Retinoid	69
Serotonin and norepinephrine reuptake inhibitor	286
Serotonin reuptake inhibitor	1,593
Thalidomide analog	31
Tumor necrosis factor blocker	28

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Loss of libido, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Loss of libido
Age	Reports	Share
Under 2	2	under 0.1%
2 to 11	1	under 0.1%
12 to 17	63	0.7%
18 to 44	4,058	45.9%
45 to 64	1,466	16.6%
65 to 74	289	3.3%
75 and over	119	1.3%
Age not given	2,836	32.1%

Sex of the patient in the reports that record Loss of libido
Sex	Reports	Share
Female	3,525	39.9%
Male	4,739	53.6%
Unknown or not given	570	6.5%

Age and sex are as the report gives them. 40.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Loss of libido: adverse event reports that record this term. https://reportedreactions.com/reaction/loss-of-libido/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Loss of libido mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page